|
|
|
|
LEADER |
01974nam a22003255i 4500 |
001 |
000289814 |
005 |
20210902153717.0 |
007 |
cr nn 008mamaa |
008 |
161006s2016 gw | s |||| 0|eng d |
020 |
|
|
|a 9783319390536
|
024 |
7 |
|
|a 10.1007/978-3-319-39053-6
|2 doi
|
040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
245 |
1 |
0 |
|a Pharmacokinetics in Drug Development :
|b Problems and Challenges in Oncology, Volume 4 /
|c edited by Peter L. Bonate, Danny R. Howard.
|
250 |
|
|
|a 1st ed. 2016.
|
260 |
# |
# |
|a Cham :
|b Springer International Publishing :
|b Imprint: Springer,
|c 2016.
|
300 |
|
|
|a XII, 330 p. 32 illus., 23 illus. in color. :
|b online resource.
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
505 |
0 |
|
|a Overview of Oncology Drug Development -- A Global Perspective on First-In-Man Dose Selection: Oncology and Beyond -- Controversies in Oncology: Size-Based vs. Fixed Dosing -- Clinical QTc Assessment in Oncology -- Expediting Drug Development: Breakthrough Therapy Designation -- Pharmacokinetics and Pharmacodynamics of Tyrosine Kinase Inhibitors -- Combination Development -- Role of Pharmacokinetics-Pharmacodynamics in Biosimilar Assessments -- Pharmacokinetics and Pharmacogenetics of Metronomics -- Modeling Tumor Growth in Animals and Humans: an Evolutionary Approach -- Practical Considerations for Clinical Pharmacology in Oncology Drug Development: A Survey of Approvals from 2009-2015 -- New Advancements in Exposure-Response Analysis to Inform Regulatory Decision-Making .
|
650 |
|
0 |
|a Pharmaceutical technology.
|
650 |
|
0 |
|a Oncology .
|
650 |
|
0 |
|a Biomathematics.
|
650 |
1 |
4 |
|a Pharmaceutical Sciences/Technology.
|
650 |
2 |
4 |
|a Oncology.
|
650 |
2 |
4 |
|a Mathematical and Computational Biology.
|
700 |
1 |
|
|a Bonate, Peter L.
|e editor.
|
700 |
1 |
|
|a Howard, Danny R.
|e editor.
|
710 |
2 |
|
|a SpringerLink (Online service)
|
773 |
0 |
|
|t Springer eBooks
|